Imipenem/Cilastatin Hikma Farmacêutica Portugal (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands and leading to cell lysis. Cilastatin, included in the formulation, blocks renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby extending its plasma and urinary concentrations and enhancing antibacterial activity.

The dose of Imipenem/Cilastatin is individualized by the prescribing clinician based on the type and severity of infection, the patient’s renal function, body weight, and other clinical factors. No fixed dosing regimen is provided here; healthcare professionals should follow local guidelines and adjust dosing as needed.

Safety data for Imipenem/Cilastatin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential therapeutic benefit justifies the potential risk to the fetus. Caution is also advised for nursing mothers, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Imipenem/Cilastatin. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if required), and any necessary import documentation.

Imipenem/Cilastatin offers a broad spectrum of activity comparable to other carbapenems such as meropenem or ertapenem, but it includes cilastatin to inhibit renal dehydropeptidase I, which can enhance renal stability. Choice among carbapenems often depends on local resistance patterns, dosing convenience, and specific pharmacokinetic properties; clinicians should consider these factors when selecting therapy.

Imipenem/Cilastatin powder for injection should be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or shaking the vial. Maintaining the cold‑chain ensures drug stability and potency until reconstitution.

The medication is supplied as a sterile powder that must be reconstituted with a compatible diluent. After preparation, it is administered intravenously, typically via infusion over a prescribed period. Administration should be performed by qualified healthcare personnel in a clinical setting, following aseptic technique and manufacturer instructions.

Serious adverse events include seizures, especially in patients with renal impairment or when high doses are used, and severe hypersensitivity reactions such as anaphylaxis. Additionally, Clostridioides difficile‑associated colitis can occur, and renal toxicity may develop in susceptible individuals. Prompt medical attention is required if any of these events are suspected.

Imipenem/Cilastatin is contraindicated in patients with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, as the drug can reduce valproate levels and increase seizure risk.